Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation

Transplant International

Volumn 17, Issue 3, 2004, Pages 109-119

  Siirtola, Arja ^a   Antikainen, Marjatta ^b   Ala Houhala, Marja ^c   Koivisto, Anna Maija ^c,d   Solakivi, Tiina ^a,c   Jokela, Hannu ^c   Lehtimäki, Terho ^c   Holmberg, Christer ^b   Salo, Matti K ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Cholesterol; Cyclosporine; Methylprednisolone; Paediatric; Transplantation; Triglyceride

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; WARFARIN;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

BODY HEIGHT; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LIPIDS; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TRIGLYCERIDES;

EID: 2442683974     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00414.x     Document Type: Article

References (56)

1. Lindholm A, Albrectsen D, Frödin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60:451.
2. Mullins PA, Cary NR, Sharples L, et al. Coronary occlusive disease and late graft failure after cardiac transplantation. Br Heart J 1992; 68:260.
3. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:985.
4. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant recipients. Nephrol Dial Transplant 1999; 14:648.
5. Larosa JC, Hunninghake D, Bush D, et al. The cholesterol facts, a summary of evidence relating dietary facts, serum cholesterol, and coronary heart disease. Circulation 1990; 81:1721.
6. Markell MS, Armenti V, Danovitch G, Sumrani N. Hyperlipidemia and glucose intolerance in the postrenal transplant patient. J Am Soc Nephrol 1994; 4:S37.
7. Munoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995; 1:29.
8. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with recommendations. J Am Coll Cardiol 1992; 19:1315.
9. McDiarmid SV, Gornbein JA, Fortunat M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992; 53:109.
10. Singh A, Tejani C, Benfield M, Tejani A. Sequential analysis of the lipid profile of children post-renal transplantation. Pediatr Transplant 1998; 2:216.
11. Chin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000; 4:193.
12. McDonald PC, Kenyon JA, McManus BC. The role of lipids in transplant vascular disease. Lab Invest 1998; 78:1187.
13. Gao SZ, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987; 76:V56.
14. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49:518.
15. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 1996; 7:971.
16. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63:331.
17. Pahl E, Crawford SE, Wax DF, Backer CL, Mavroudis C, Gidding S. Safety and efficacy of pravastatin in pediatric heart transplant recipients. J Heart Lung Transplant 2001; 20:230.
18. Chin C, Gamberg P, Miller J, Luikart H, Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002; 21:1213.
19. Bittar AE, Ratcliffe PJ, Raine AEG, et al. The prevalence of hyperlipidemia in renal transplant recipients. Transplantation 1990; 50:987.
20. Arnadottir M, Thysell H, Nilsson-Ehle P. Treatment of hyperlipidemia in renal transplant recipients. Transplantation 1997; 63:339.
21. Laine J, Jalanko H, Saarinen-Pihkala UM, Hockerstedt K, Leijala M, Holmberg C, Heikinheimo M. Successful liver transplantation after induction chemotherapy in children with inoperable, multifocal primary hepatic malignancy. Transplantation 1999; 67:1369.
22. Laine J, Krogerus L, Fyhrquist F, Jalanko H, Rönnholm K, Holmberg C. Renal function and histopathologic changes in children after liver transplantation. J Pediatr 1994; 125:863.
23. Laine J, Krogerus L, Jalanko H, Rönnholm K, Holmberg C. Renal allograft histology and correlation with function in children on triple therapy. Nephrol Dial Transplant 1995; 10:95.
24. Laine J, Jalanko H, Leijala M, Sairanen H, Holmberg C. Kidney function in cyclosporine-treated pediatric heart transplant recipients. J Heart Lung Transplant 1997; 16:1217.
25. Laine J, Jalanko H, Holthöfer H, et al. Post-transplantation nephrosis in congenital nephrotic syndrome of the Finnish type. Kidney Int 1993; 44:867.
26. Sorva R, Lankinen S, Tolppanen EM, Perheentupa J. Variation of growth in height and weight in children. II. After infancy. Acta Pediatr 1990; 79:498.
27. Nuutinen ME, Turtinen J, Pokka T, et al. Obesity in children, adolescents and young adults. Ann Med 1991; 23:41.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499.
30. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991; 57:401.
31. Querfeld U. Disturbances of lipid metabolism in children with chronic renal failure. Pediatr Nephrol 1993; 7:749.
32. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant recipients. Medicine (Baltimore) 1987; 66:309.
33. Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Krämer-Guth A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 1999; Suppl 71:S235.
34. Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8:209.
35. Bagdade JD, Yee E, Albers JJ, Pykalisto OJ. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metabolism 1976; 25:533.
36. Krausz Y, Bar-On H, Shafrir E. Origin and pattern of glucocorticoid-induced hyperlipidemia in rats. Dose-dependent bimodal changes in serum lipids and lipoproteins in relation to hepatic lipogenesis and tissue lipoprotein lipase activity. Biochim Biophys Acta 1981; 663:69.
37. Hokken-Koelega AC, Stijnen T, Dejong RC, et al. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int 1996; 49:S128.
38. Vathsala A, Weinberg R, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisolone-treated renal transplant recipients. Transplantation 1989; 48:37.
39. Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85:632.
40. Kasiske BL, Tortorice KL, Heim-Duthoi KL, Awni WM, Venkatesvara R. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17:700.
41. Kubo SH, Peters JR, Knutson KR, et al. Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1992; 70:520.
42. Aakhus S, Dahl K, Wideroe TE. Hyperlipidemia in renal transplant patients. J Int Med 1996; 239:407.
43. Divakar D, Bailey RR, Frampton CM, George PM, Walmsley TA, Murphy J. Hyperlipidemia in renal transplant recipients. Nephron 1991; 59:423.
44. Stamler JS, Vaughan DE, Rudd A, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62:1268.
45. Farmer JA, Ballantyne CM, Frazier OH, et al. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol 1991; 18:926.
46. Keogh A, Simons L, Spratt P, et al. Hyperlipidemia after heart transplantation. J Heart Transplant 1988; 7:171.
47. Bergesio F, Monzani G, Ciuti R, et al. Lipids and apolipoprotein changes during the progression of renal failure. Clin Nephrol 1992; 38:264.
48. Warwick GL, Packard CJ. Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant 1993; 8:385.
49. Vergani C, Trovato G, Delù A, Pietrogrande M, Dioguardi N. Serum total lipids, lipoprotein cholesterol, and apolipoprotein A in acute viral hepatitis and chronic liver disease. J Clin Pathol 1978; 31:772.
50. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25:541.
51. Antikainen M, Holmberg C, Taskinen MR. Growth, serum lipoproteins and apoproteins in infants with congenital nephrosis. Clin Nephrol 1992; 38:254.
52. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18:353.
53. Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects of lipoproteins. Transplantation 1994; 57:1479.
54. Imakawa D, Dawson III S, Holt CD, et al. Hyperlipidemia after liver transplantation. Transplantation 1996; 62:934.
55. Al Rayyes O, Wallmark A, Floren CH. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology 1997; 26:967.
56. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23:57.